RxDoctor Payments Data

Amber Ervin, DO

Internal Medicine · Brownwood, TXNPI 1811139371

Payments from drug & device makers

$1,131in general payments, 2019–2025

Across 67 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$155
  • Idorsia Pharmaceuticals US Inc$151
  • AstraZeneca$142
  • Pfizer$100
  • Novo Nordisk$81
  • Novartis$61
  • plus $441 from 13 others

What the payments were for

  • Food & beverage$1,131100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,131 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$158,723
Medicare patients
420
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$65,899
FarxigaDapagliflozin Propanediol69$50,498
TrulicityDulaglutide49$45,456
MyrbetriqMirabegron129$45,053
OzempicSemaglutide40$40,839
XareltoRivaroxaban58$36,967
JanuviaSitagliptin Phosphate51$25,316
JardianceEmpagliflozin54$23,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,761
RybelsusSemaglutide13$16,971
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,389
LinzessLinaclotide17$12,053
Tresiba Flextouch U-100Insulin Degludec13$10,231
BrilintaTicagrelor40$8,855
Dexlansoprazole DrDexlansoprazole36$8,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$142$75,742127 claims
PfizerEliquis, Abrysvo$100$69,358144 claims
Novo NordiskOzempic, Rybelsus$81$57,81053 claims
Lilly USA, LLCTrulicity$51$45,45649 claims
Astellas Pharma US IncMyrbetriq$22$45,053129 claims
Johnson & JohnsonXarelto$53$36,96758 claims
MerckJanuvia, Belsomra$25$30,44564 claims
Boehringer IngelheimJardiance$51$23,67254 claims
AbbVieLinzess, Synthroid$155$13,73033 claims
NovartisEntresto$61$5,12014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Brownwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →